Call Us 080-41656200 (Mon-Sat: 10AM-8PM)
Free Shipping above Rs. 1499
Cash On Delivery*

Sensitising cervix against cancer

 

Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

 

Check Your Delivery Options

 
Rs. 3,651

Availability: In stock

 
  • Product Description
 

The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer.

Product Specifications
SKU :COC30095
AuthorSanjoy Roy,Devleena Mukherjee and Debarshi Lahiri
LanguageEnglish
BindingPaperback
Number of Pages76
Publishing Year2012-04-06T00:00:00.000
ISBN978-3659146695
Edition1 st
Book TypeMedicine
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-07-29 00:00:00
0 Review(s)